Symposium | Targeted therapies for classic Hodgkin lymphoma

Symposium | Panel discussion | How to sequence targeted therapies in classic Hodgkin lymphomaПодробнее

Relapsed or refractory classical Hodgkin lymphoma - with Dr Robin Gasiorowski. EHA 2020Подробнее

Overview of novel restore and target treatment approach to classical Hodgkin lymphomaПодробнее

Novel Treatments for Lymphoma: Focus on Targeted TherapiesПодробнее

Optimal therapy sequencing for Hodgkin lymphomaПодробнее

Conversations with Innovators: Joseph Connors, MD, on Targeted Therapy for Hodgkin LymphomaПодробнее

Effective Therapies in Classical Hodgkin LymphomaПодробнее

Symposium | Targeted therapies in classic Hodgkin lymphoma: Future perspectivesПодробнее

Cellular and targeted therapies for Hodgkin lymphomaПодробнее

What is Targeted Therapy for Treating Non-Hodgkin Lymphomas? (From Chapter 3)Подробнее

Immune targeting of the microenvironment in classical Hodgkin lymphomaПодробнее

How I Treat Hodgkin Lymphoma - Joseph Connors, MDПодробнее

Improving Targeted Therapies for Patients with Previously Untreated Advanced Classic Hodgkin LymphomПодробнее

Frontline Treatment of Classical Hodgkin LymphomaПодробнее

Targeting CD30 in Classical Hodgkin LymphomaПодробнее

Emerging Therapies for Non Hodgkin's Lymphoma (NHL)Подробнее

17. Targeted therapy for non-Hodgkin lymphoma – Dr Cathy BurtonПодробнее

Updated ECHELON-1 Findings Demonstrate Potential Toxicities of Brentuximab Vedotin Combo in cHLПодробнее

The Impact of CheckMate-205 for Patients With Classical Hodgkin LymphomaПодробнее